U
Endonovo Therapeutics, Inc.
ENDV
$0.0002
$0.000.00%
E
Sell
3/27/2024Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 3/27/2024 due to a decline in the volatility index.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 3/27/2024 due to a decline in the volatility index.
D
Sell
3/11/2024Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 3/11/2024 due to a substantial increase in the valuation index and solvency index.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 3/11/2024 due to a substantial increase in the valuation index and solvency index.
E
Sell
3/14/2023Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D on 03/14/2023.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D on 03/14/2023.
D
Sell
3/10/2023Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D from D- on 3/10/2023 due to a large increase in the total return index and volatility index.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D from D- on 3/10/2023 due to a large increase in the total return index and volatility index.
D
Sell
2/23/2023Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 02/23/2023.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 2/8/2023 due to a noticeable decline in the solvency index and valuation index. Debt to equity increased from -0.38 to -0.37.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 2/8/2023 due to a noticeable decline in the solvency index and valuation index. Debt to equity increased from -0.38 to -0.37.
D
Sell
8/23/2022Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 8/23/2022 due to a noticeable increase in the solvency index and growth index. Earnings per share increased from -$0.0305 to -$0.02.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 8/23/2022 due to a noticeable increase in the solvency index and growth index. Earnings per share increased from -$0.0305 to -$0.02.
E
Sell
5/20/2022Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 5/20/2022 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0326 to -$0.0305, and EBIT declined 29.96% from -$373.8 to -$485.8.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 5/20/2022 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0326 to -$0.0305, and EBIT declined 29.96% from -$373.8 to -$485.8.
D
Sell
5/5/2022Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 05/05/2022.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 05/05/2022.
E
Sell
4/20/2022Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 04/20/2022.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 04/20/2022.
D
Sell
11/22/2021Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 11/22/2021.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 11/22/2021.
E
Sell
11/8/2021Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index and total return index.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index and total return index.
D
Sell
8/24/2021Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D- from D on 8/24/2021 due to a noticeable decline in the growth index. Total revenue declined 12.68% from $34.7 to $30.3.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D- from D on 8/24/2021 due to a noticeable decline in the growth index. Total revenue declined 12.68% from $34.7 to $30.3.
D
Sell
5/26/2021Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D from D- on 5/26/2021 due to an increase in the growth index and volatility index. Total revenue increased 201.74% from $11.5 to $34.7, earnings per share increased from -$0.1015 to -$0.0645, and EBIT increased 13.68% from -$684 to -$590.4.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D from D- on 5/26/2021 due to an increase in the growth index and volatility index. Total revenue increased 201.74% from $11.5 to $34.7, earnings per share increased from -$0.1015 to -$0.0645, and EBIT increased 13.68% from -$684 to -$590.4.
D
Sell
4/14/2021Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D- from D on 4/14/2021 due to a noticeable decline in the growth index and volatility index. Operating cash flow declined 99.48% from -$96.7 to -$192.9, total revenue declined 71.25% from $40 to $11.5, and earnings per share declined from -$0.07 to -$0.1015.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D- from D on 4/14/2021 due to a noticeable decline in the growth index and volatility index. Operating cash flow declined 99.48% from -$96.7 to -$192.9, total revenue declined 71.25% from $40 to $11.5, and earnings per share declined from -$0.07 to -$0.1015.
D
Sell
8/20/2020Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D from D- on 8/20/2020 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 47.91% from -$297.2 to -$154.8, and EBIT increased 11.45% from -$679.6 to -$601.8.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D from D- on 8/20/2020 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 47.91% from -$297.2 to -$154.8, and EBIT increased 11.45% from -$679.6 to -$601.8.
D
Sell
6/12/2020Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 6/12/2020 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$5.9664 to -$0.14, EBIT increased 6.9% from -$730 to -$679.6, and operating cash flow increased 3.63% from -$308.4 to -$297.2.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D- from E+ on 6/12/2020 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$5.9664 to -$0.14, EBIT increased 6.9% from -$730 to -$679.6, and operating cash flow increased 3.63% from -$308.4 to -$297.2.
E
Sell
5/1/2020Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 0.03 to 0.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to E+ from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 0.03 to 0.
D
Sell
6/18/2019Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 6/18/2019 due to a decline in the volatility index and total return index.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 6/18/2019 due to a decline in the volatility index and total return index.
D
Sell
6/3/2019Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 6/3/2019 due to an increase in the growth index and valuation index. Operating cash flow increased 26.24% from -$716.1 to -$528.2, EBIT increased 21.22% from -$1.03M to -$813, and total revenue increased 6.89% from $42.1 to $45.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 6/3/2019 due to an increase in the growth index and valuation index. Operating cash flow increased 26.24% from -$716.1 to -$528.2, EBIT increased 21.22% from -$1.03M to -$813, and total revenue increased 6.89% from $42.1 to $45.
D
Sell
1/10/2019Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 1/10/2019 due to a decline in the total return index and volatility index.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 1/10/2019 due to a decline in the total return index and volatility index.
D
Sell
12/26/2018Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 12/26/2018 due to an increase in the total return index, volatility index and valuation index.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 12/26/2018 due to an increase in the total return index, volatility index and valuation index.
D
Sell
11/15/2018Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 11/15/2018 due to a decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.0036 to -$0.02, EBIT declined 26.75% from -$816.7 to -$1.04M, and operating cash flow declined 11.97% from -$741.6 to -$830.4.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 11/15/2018 due to a decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.0036 to -$0.02, EBIT declined 26.75% from -$816.7 to -$1.04M, and operating cash flow declined 11.97% from -$741.6 to -$830.4.
D
Sell
9/11/2018Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 9/11/2018 due to an increase in the total return index and volatility index.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 9/11/2018 due to an increase in the total return index and volatility index.
D
Sell
8/24/2018Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 8/24/2018 due to a noticeable decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.01 to 0.01.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 8/24/2018 due to a noticeable decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.01 to 0.01.
D
Sell
8/14/2018Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 8/14/2018 due to an increase in the total return index.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 8/14/2018 due to an increase in the total return index.
D
Sell
7/20/2018Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 7/20/2018 due to a decline in the volatility index.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 7/20/2018 due to a decline in the volatility index.
D
Sell
5/18/2018Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 5/18/2018 due to an increase in the volatility index, total return index and solvency index. Debt to equity declined from -0.5 to -0.63, and the quick ratio increased from 0.01 to 0.01.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 5/18/2018 due to an increase in the volatility index, total return index and solvency index. Debt to equity declined from -0.5 to -0.63, and the quick ratio increased from 0.01 to 0.01.
D
Sell
5/7/2018Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 5/7/2018 due to a noticeable decline in the total return index, efficiency index and volatility index.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 5/7/2018 due to a noticeable decline in the total return index, efficiency index and volatility index.
D
Sell
3/7/2018Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 3/7/2018 due to an increase in the total return index.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 3/7/2018 due to an increase in the total return index.
D
Sell
2/20/2018Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 2/20/2018 due to a decline in the total return index and volatility index.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 2/20/2018 due to a decline in the total return index and volatility index.
D
Sell
2/5/2018Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 2/5/2018 due to an increase in the total return index and growth index. EBIT increased 52.45% from -$2.18M to -$1.04M, and operating cash flow increased 7.9% from -$913.6 to -$841.4.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 2/5/2018 due to an increase in the total return index and growth index. EBIT increased 52.45% from -$2.18M to -$1.04M, and operating cash flow increased 7.9% from -$913.6 to -$841.4.
D
Sell
5/12/2017Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 5/12/2017 due to a large decline in the growth index and solvency index. Earnings per share declined from -$0.0057 to -$0.05, and debt to equity increased from -0.24 to -0.15.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 5/12/2017 due to a large decline in the growth index and solvency index. Earnings per share declined from -$0.0057 to -$0.05, and debt to equity increased from -0.24 to -0.15.
D
Sell
4/18/2017Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 4/18/2017 due to a major increase in the growth index. EBIT increased 51.72% from -$1.31M to -$632.8, earnings per share increased from -$0.018 to -$0.0101, and operating cash flow increased 15.07% from -$775.6 to -$658.7.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 4/18/2017 due to a major increase in the growth index. EBIT increased 51.72% from -$1.31M to -$632.8, earnings per share increased from -$0.018 to -$0.0101, and operating cash flow increased 15.07% from -$775.6 to -$658.7.
D
Sell
2/10/2017Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 2/10/2017 due to a large decline in the total return index.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from D+ on 2/10/2017 due to a large decline in the total return index.
D
Sell
11/17/2016Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 11/17/2016 due to an increase in the total return index, growth index and valuation index. EBIT increased 36.53% from -$2.07M to -$1.31M.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 11/17/2016 due to an increase in the total return index, growth index and valuation index. EBIT increased 36.53% from -$2.07M to -$1.31M.
D
Sell
8/12/2016Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from C- on 8/12/2016 due to a large decline in the growth index and total return index. Earnings per share declined from -$0.0085 to -$0.0131, EBIT declined 47.29% from -$1.4M to -$2.07M, and operating cash flow declined 41.96% from -$424.9 to -$603.2.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D from C- on 8/12/2016 due to a large decline in the growth index and total return index. Earnings per share declined from -$0.0085 to -$0.0131, EBIT declined 47.29% from -$1.4M to -$2.07M, and operating cash flow declined 41.96% from -$424.9 to -$603.2.
C
Hold
4/7/2016Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to C- from D+ on 4/7/2016 due to an increase in the growth index, valuation index and total return index. Total revenue increased 100% from -$400 to $0, and operating cash flow increased 50.77% from -$429.2 to -$211.3.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to C- from D+ on 4/7/2016 due to an increase in the growth index, valuation index and total return index. Total revenue increased 100% from -$400 to $0, and operating cash flow increased 50.77% from -$429.2 to -$211.3.
D
Sell
3/11/2016Downgrade
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D+ from C on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Earnings per share declined from -$0.0057 to -$0.0135, operating cash flow declined 132% from -$185 to -$429.2, and total revenue declined 121.05% from $1.9 to -$400.
Endonovo Therapeutics, Inc. (ENDV) was downgraded to D+ from C on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Earnings per share declined from -$0.0057 to -$0.0135, operating cash flow declined 132% from -$185 to -$429.2, and total revenue declined 121.05% from $1.9 to -$400.
C
Hold
3/2/2015Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to C from C- on 3/2/2015 due to a large increase in the volatility index and total return index.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to C from C- on 3/2/2015 due to a large increase in the volatility index and total return index.
C
Hold
12/1/2014Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to C- from D+ on 12/1/2014 due to a significant increase in the efficiency index, growth index and volatility index. Total revenue increased 25.61% from $16.4 to $20.6.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to C- from D+ on 12/1/2014 due to a significant increase in the efficiency index, growth index and volatility index. Total revenue increased 25.61% from $16.4 to $20.6.
D
Sell
9/2/2014Upgraded
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 9/2/2014 due to a substantial increase in the total return index, growth index and volatility index. Operating cash flow increased 47.78% from -$195.9 to -$289.5, and EBIT increased 45.72% from -$567.1 to -$826.4.
Endonovo Therapeutics, Inc. (ENDV) was upgraded to D+ from D on 9/2/2014 due to a substantial increase in the total return index, growth index and volatility index. Operating cash flow increased 47.78% from -$195.9 to -$289.5, and EBIT increased 45.72% from -$567.1 to -$826.4.
D
Sell
3/3/2014Upgraded
Hanover Portfolio Acquisitions, Inc. (HVPA) was upgraded to D from D- on 3/3/2014 due to a significant increase in stability, valuation and total return.
Hanover Portfolio Acquisitions, Inc. (HVPA) was upgraded to D from D- on 3/3/2014 due to a significant increase in stability, valuation and total return.
OTC PK
04/03/2025 9:30AM Eastern
Quotes delayed
